Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 16;15(1):e0227624. doi: 10.1371/journal.pone.0227624

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Chen et al

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

Fig 2 — MCAO significantly augmented the neurologic deficit, which was significantly attenuated by LRIP treatment. Additionally, cohort 4, where ketamine-xylazine was used during LRIP, exhibited a significant difference compared with cohort 2, where isoflurane was used during LRIP. The effects of LRIP on NDS persisted across the time points. Data are presented as mean ± SD. *p < 0.05 when compared cohort 1 vs cohort 2, ^#p < 0.05, ^##p < 0.01, ^###p < 0.001 when compared cohort 3 vs cohort 4, and ^†p < 0.05 when compared cohort 2 vs cohort 4.